About Contraline
Contraline is a company based in Charlottesville (United States) founded in 2015 by Kevin Eisenfrats. It operates as a HealthTech. Contraline has raised $18.62 million across 11 funding rounds from investors including HHS, Afton Scientific and Google Ventures. The company has 7 employees as of December 31, 2021. Contraline offers products and services including ADAM™. Contraline operates in a competitive market with competitors including Kerecis, Kitotech Medical, microMend, Alafair Biosciences and PolyNovo, among others.
- Headquarter Charlottesville, United States
- Employees 7 as on 31 Dec, 2021
- Founders Kevin Eisenfrats
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Contraline, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$18.62 M (USD)
in 11 rounds
-
Latest Funding Round
$291.44 K (USD), Grant
Sep 10, 2024
-
Investors
HHS
& 16 more
-
Employee Count
7
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Contraline
Contraline offers a comprehensive portfolio of products and services, including ADAM™.
An implant is developed for long-lasting male contraception.
People of Contraline
Unlock access to complete
Unlock access to complete
Funding Insights of Contraline
Contraline has successfully raised a total of $18.62M across 11 strategic funding rounds. The most recent funding activity was a Grant round of $291.44 thousand completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Contraline
Contraline has secured backing from 17 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include HHS, Afton Scientific and Google Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked | |
|
Investments are focused on reproductive healthcare startups by Rhia Ventures.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Contraline
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Contraline
Investment portfolio details for Contraline
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Contraline
Detailed financials for Contraline
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Contraline Comparisons
Peer comparison for Contraline
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Contraline
Contraline operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kerecis, Kitotech Medical, microMend, Alafair Biosciences and PolyNovo, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Fish-skin acellular dermal matrix technology is provided for wound treatments.
|
|
| Locked | Locked | Locked |
Developer of a device to close wounds, lacerations, and surgical incisions
|
|
| Locked | Locked | Locked |
Solutions for treating dermatological disorders are provided by microMend.
|
|
| Locked | Locked | Locked |
Biomaterials and devices for internal wound healing are developed.
|
|
| Locked | Locked | Locked |
Developer of biodegradable temporising matrix for treating traumatic wounds
|
Detailed competitors of Contraline
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Contraline
Complete news archive for Contraline
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Contraline
Contraline was founded in 2015.
Contraline is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
Kevin Eisenfrats is the current CEO of Contraline. They have also founded this company.
Contraline is a funded company, having raised a total of $18.62M across 11 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Contraline is 7.
Contraline is engaged in the development of male contraception technologies. The company is based in the healthcare sector, specifically targeting medical devices for contraception. Their flagship product, ADAM, is designed as the worlds first implant for long-lasting and reversible male contraception, comparable to an IUD for men. Clinical trials for this investigational device have been initiated, marking a significant advancement in male contraceptive options since the vasectomy.
Contraline's top competitors include Kerecis, Kitotech Medical and Alafair Biosciences.
Contraline offers ADAM™.
Contraline has 17 investors. Key investors include HHS, Afton Scientific, Google Ventures, Rhia Ventures, and ShangBay Capital.